Zacks Investment Research
11 Mar 2026, 14:06 UTC · 27w ago
Verdict
Headline takes no side. We score RLAY +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Relay Therapeutics' lead candidate zovegalisib (RLY-2608) has shown potential improvements in tolerability and progression-free survival compared to standard-of-care therapies in the phase III ReDiscover-2 study.
So whatPositive clinical efficacy and tolerability signals for a phase III oncology asset directly improve the drug's commercial viability and the company's fundamental valuation.
More positive than 99% of claims this week
The consensus EPS estimate for Relay Therapeutics' upcoming quarter was revised 15.7% higher over the last 30 days.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 85% of claims this week
Relay Therapeutics' quarterly revenues are expected to be $15.35 million, up 99.9% year-over-year.
More positive than 77% of claims this week
Relay Therapeutics is expanding zovegalisib's clinical development by studying triplet regimens with CDK4/6 inhibitors for earlier-line use and evaluating it for PIK3CA-driven vascular anomalies.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
Shares rose 5.4% on high volume due to growing investor optimism regarding its clinical pipeline and positive earnings estimate revisions.
More positive than 52% of ticker scores this week
Mentioned as having high page view growth (142.96%), indicating increased investor interest.
More positive than 52% of ticker scores this week
Mentioned as having high page view growth (210.31%), indicating increased investor interest.
More positive than 52% of ticker scores this week
Mentioned as having high page view growth (129.10%), indicating increased investor interest.
More positive than 52% of ticker scores this week
Mentioned as having the highest page view growth (258.17%), indicating increased investor interest.
More positive than 52% of ticker scores this week
Mentioned as having high page view growth (165.31%), indicating increased investor interest.
More positive than 52% of ticker scores this week
Mentioned as having high page view growth (111.37%), indicating increased investor interest.
More negative than 66% of ticker scores this week
The stock closed the last trading session 0.7% lower.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
More positive than 1% of relationship scores this week
[mutual] Both companies are identified as belonging to the Zacks Medical - Drugs industry.
+81.0%
Price agrees with the score
$19.35 vs $10.69 close before publication (Mar 10) · not market-adjusted
RLAY chart →
